The Sapien 3 transcatheter heart valve was approved by the FDA for an expanded indication that now includes patients with existing bioprosthetic aortic and mitral valves. The Sapien XT and CoreValve have been approved for valve-in-valve procedures on aortic bioprostheses, but this is the first regulatory clearance for operators to perform such procedures on mitral bioprostheses as well. (Cardiovascular Business)